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Abstract
Background: Without appropriate cellular models the etiology of idiopathic Parkinson’s disease remains unknown. We
recently reported a novel patient-derived cellular model generated from biopsies of the olfactory mucosa (termed olfactory
neurosphere-derived (hONS) cells) which express functional and genetic differences in a disease-specific manner.
Transcriptomic analysis of Patient and Control hONS cells identified the NRF2 transcription factor signalling pathway as the
most differentially expressed in Parkinson’s disease.
Results: We tested the robustness of our initial findings by including additional cell lines and confirmed that hONS cells
from Patients had 20% reductions in reduced glutathione levels and MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] metabolism compared to cultures from healthy Control donors. We
also confirmed that Patient hONS cells are in a state of oxidative stress due to higher production of H2O2 than Control
cultures. siRNA-mediated ablation of NRF2 in Control donor cells decreased both total glutathione content and MTS
metabolism to levels detected in cells from Parkinson’s Disease patients. Conversely, and more importantly, we showed that
activation of the NRF2 pathway in Parkinson’s disease hONS cultures restored glutathione levels and MTS metabolism to
Control levels. Paradoxically, transcriptomic analysis after NRF2 pathway activation revealed an increased number of
differentially expressed mRNAs within the NRF2 pathway in L-SUL treated Patient-derived hONS cells compared to L-SUL
treated Controls, even though their metabolism was restored to normal. We also identified differential expression of the
PI3K/AKT signalling pathway, but only post-treatment.
Conclusions: Our results confirmed NRF2 as a potential therapeutic target for Parkinson’s disease and provided the first
demonstration that NRF2 function was inducible in Patient-derived cells from donors with uniquely varied genetic
backgrounds. However, our results also demonstrated that the response of PD patient-derived cells was not co-ordinated in
the same way as in Control cells. This may be an important factor when developing new therapeutics.
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Introduction
Parkinson’s disease (PD) is a late onset disorder recognisable by a
characteristic cluster of motor and non-motor neurological symp-
toms, attributed to region-specific neurodegeneration, which includes
the prominent loss of the dopaminergic nigro-striatal tracts [1].
Idiopathic PD is considered a ‘‘complex’’ disease arising from
interactions between environmental risk factors with multiple risk-
associated genes in individual patients. Research into PD has utilised
several animal models, either based on xenobiotic exposure, genetic
manipulation, or a combination of both to induce PD-like phenotypes
[reviewedin2].Whilstmuchhasbeenlearntfromsuchmodels,those
available are not without limitations. In particular, the toxin-based
models, while reproducing the nigro-striatal deficit, fail to replicate
the classic pathological hallmarks and the insidious, progressive
nature of the human disease. The genetic models also fail to
phenocopy the human disease in that they generally lack a
parkinsonian behavioural phenotype and/or the characteristic
pathological features of the human disease. Moreover, there is a
distinct inability of either approach to model sporadic, late-onset
disease, which accounts for over 90% of human cases [3], which
highlights the need for alternative, but complementary approaches.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21907The symptoms of PD include neuronal dysfunction in regions
outside the nigro-striatal pathway. For example, defects in
olfactory function are at least as common as movement
dysregulation in PD [4]. The olfactory mucosa, the organ of smell
in the nose, is a neuroepithelium that regenerates throughout life
producing neurons and glia, and is accessible by biopsy in human
adults [5,6]. We have used these features to establish a novel
cellular model of PD, termed human olfactory neurosphere-
derived (hONS) cell lines, from olfactory mucosa biopsies from
multiple PD patients and healthy Controls [7].
Molecular mechanisms underlying the phenotypes observed in
sporadic PD are as yet unknown, but several have been implicated,
including decreased levels of glutathione (GSH), proteasomal
impairment, oxidative damage and mitochondrial dysfunction
[1,3,8]. These are not mutually exclusive and the causes of PD
are likely to be multifactorial with pathways acting in concert to
cause degeneration. This is supported by the observation that the
PARK proteins which are altered in familial PD cases, are involved
inboth mitochondrial and proteasomalregulation [3,9].Assessment
of hONS cells metabolic function in PD compared to Controls
hONS cultures revealed decreases in both MTS metabolism and
reduced GSH content [7], results consistent with PD post-mortem
brain specimens [10,11,12]. MTS metabolism is a generalised
measure of cellular metabolic activity, based on reduction by
NAD(P)H-dependent dehydrogenase enzymes [13,14], whereas
reduced glutathione levels are a marker of oxidative stress buffering
capacity [15]. Importantly, these same metabolic functions were
specific for PD, as they were unaltered in hONS cultures derived
from schizophrenia patients [7]. Thus, the hONS cellular model
captures differences in idiopathic Parkinson’s disease, based on
comparison of multiple cell lines from PD patients and healthy
Controls, thereby identifying disease-specific differences on a
background of genotypic and phenotypic variability reflective of
that within the normal human population.
Gene expression profiling of PD and Control hONS cells
revealed a significant dysregulation of pathways with relevance to
Parkinson’s disease, with the most highly ranked of these being the
‘NRF2-mediated oxidative stress response’ [7]. NRF2 is transcrip-
tion factor that induces expression of detoxification enzymes such
as the NAD(P)H dehydrogenase NQO1 and glutathione synthetic
enzymes in response to oxidants and reactive oxygen species by
binding to the antioxidant response element (ARE) within gene
promoters [16]. Under basal conditions, NRF2 is retained in the
cytoplasm by KEAP1, a protein that co-ordinates ubiquitylation of
NRF2, thereby promoting its degradation [17]. The KEAP1 -
NRF2 interaction is inhibited under oxidative stress, allowing
NRF2 to enter the nucleus and induce antioxidant gene
expression, including genes that synthesize glutathione. The
protective effects of the NRF2 transcription factor against PD-
associated toxins such as MPTP and rotenone has been an area of
intense research activity. Multiple studies have been conducted in
rodent or transformed (e.g. neuroblastoma) human cell line models
culminating in NRF2 being touted as a ‘novel therapeutic target’
for PD intervention [18] due to the ability to pharmacologically
inhibit the KEAP1 - NRF2 interaction (for example, by treatment
with L-Sulforaphane [L-SUL, reference 19]) and thereby
concomitantly inhibit proteasomal degradation of NRF2, and
increase NRF2 target gene expression. Notably, neuronal cultures
from Nrf2-null mice also show an approximate 15% decrease in
basal glutathione levels compared to control neurons [20], and
depletion of glutathione specifically within catecholaminergic
neurons results in an age-related neurodegeneration in mice
[21]. Post-mortem brain studies are also consistent with a role for
NRF2 in PD, as it is detected in the nucleus of remaining neurons
within the substantia nigra [22], suggesting that the remaining cells
attempt to induce downstream detoxification mechanisms.
Despite these studies, the extent and nature of cellular responses
to NRF2 activation have not been established for any PD patient-
derived model. Here, we focused on the functional rescue of the
GSH and MTS metabolism deficiencies detected in hONS cells
from PD patients, by starting with interrogation of the NRF2
pathway, previously identified as dys-regulated in this model [7].
We show for the first time that Parkinson’s disease patient cells
responded to NRF2 activation, such that cellular metabolic
function was restored to levels seen in the Control donor-derived
cells. Critically, through assessment of cell lines established from
multiple unrelated idiopathic Parkinson’s disease patients, we also
determined that the spectrum of transcriptional responses to
NRF2 activation differed in PD hONS cultures compared to
Controls.
Results
PD patient-derived hONS cells showed deficiencies in
Glutathione and MTS metabolism
Previously we reported decreased levels of reduced glutathione
and MTS metabolism in hONS cultures derived from PD patients
when compared to Control cultures [7]. To test the robustness of
these initial results, here we extended this analysis to a total of 54
donors: 26 Control and 28 PD. Although there was overlap
between the two groups, there was a 16% decrease in reduced
glutathione (p=0.016) and 18% decrease in MTS metabolism
(p=0.019) in PD-derived hONS cells (Fig S1). Other cell
metabolic functions (ATP content, chymotrypsin-like proteasome
activity, membrane integrity (LDH activity) and caspase-3/7
activation) did not differ between Control- and PD-derived
cultures (Fig S1). Potential confounders of these group differences
were either controlled for, or tested post-hoc (Fig S2). There were
similar numbers of male (Control N=15; PD N=17) and female
(Control N=11; PD N=11) donors in each group, average age
was not significantly different between groups, and there was no
correlation of any metabolic function with donor age or cell line
passage number.
These results raised the possibility that PD Patient cells are in a
state of oxidative stress. To quantify this directly, we then
measured the production of H2O2 in Control and PD cultures
(N=8 in each group) at several time-points post-seeding (Fig S1G).
At 24 hr post-seeding, Control and Patient hONS cultures had
similar levels of H2O2. For both Control and Patient cultures, the
amount of H2O2 in the medium increased over time, however
after 48 hrs, H2O2 levels were statistically significantly higher in
PD cultures, and this difference remained significant at all other
time-points (72 and 96 hr). This suggests that PD Patient hONS
are in a state of oxidative stress.
NRF2 silencing recapitulates PD-associated metabolic
deficiencies in Control hONS cells
To determine if decreased NRF2 function could account for the
decreased GSH and MTS metabolism observed in PD hONS
cultures, we silenced NRF2 using two NRF2-targeting siRNA
sequences (NRF2 #09 and NRF2 #10) in three different Control
hONS cultures (Fig 1). Decreased NRF2 protein levels were
confirmed by immunoblot of total protein lysates, and showed an
average 83% and 86% knockdown for NRF2 #09 and NRF2
#10 siRNAs respectively, when compared to negative control
transfected cells after normalisation of NRF2 protein levels to
GAPDH levels (Fig 1A,B). NQO1, a detoxification enzyme down-
stream of NRF2 [16] was also decreased by ablation of NRF2
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e21907Figure 1. NRF2 depletion recapitulates PD-associated changes in metabolic function. A. Immunoblot analysis of 3 Control hONS cell lines
transiently transfected with either negative control (Neg Cont) siRNAs or siRNAs targeting NRF2 (NRF2 #09 and NRF2#10). The protein being
detected is indicated to the left of the gel panels. B–C. Quantification of NRF2 and NQO1 protein levels relative to GAPDH protein in cultures
described in A. D–G. Total GSH content (D) and MTS metabolism (E) were both statistically significantly decreased in Control hONS transfected with
NRF2 targeting siRNAs compared to negative control siRNAs. LDH activity (F) and DNA content (G) were not affected by decreased NRF2 function. For
B–G, statistical significance was determined using ANOVA with Dunnett’s multiple comparison post-test with the following thresholds: *, p,0.05;
**, p,0.01, ***, p,0.001.
doi:10.1371/journal.pone.0021907.g001
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cells transfected in parallel revealed that both total glutathione
content (22% and 23% decreases, Fig 1D) and MTS metabolism
(12 and 17% decreases, Fig 1E) were affected by NRF2 depletion.
These decreased metabolic functions were consistent for each
NRF2 targeting siRNA used, and were statistically significantly
different from negative control siRNA cultures. In contrast, cell
membrane integrity (LDH activity, Fig 1F) and total cell number
(as determined by DNA content, Fig 1G) were unaffected. These
results suggest that decreased NRF2 function may be responsible
for the diminished glutathione and MTS metabolism levels
observed in PD hONS cultures.
NRF2 pathway induction in Patient hONS-derived cells
alters cell metabolism
Immunoblot analysis of total protein lysates of hONS cultures
revealed that expression of the NRF2 transcription factor was
similar in both Control and PD cells (Fig 2A,B). However, levels of
the NRF2 target NQO1 were decreased by approximately 50%
(p=0.0016) in the PD hONS cell lines examined (Fig 2A,C). This
result, combined with the effects of NRF2 ablation in Control
hONS cultures (Figure 1), suggested that activation of the NRF2
pathway in PD hONS cultures may be a valid approach to
restoration of the disease-associated transcriptional and metabolic
deficiencies to Control hONS culture levels.
Figure 2. NRF2 pathway components are expressed in hONS cultures. A. Immunoblot analysis of total protein lysates from 6 Control donor-
derived and 6 PD patient-derived hONS cell lines. The protein being immunodetected is indicated to the left of each gel panel. B–C. Quantitation of
NRF2 (B) and NQO1 (C) protein levels relative to GAPDH.
doi:10.1371/journal.pone.0021907.g002
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pathway with L-SUL would increase the glutathione content and
MTS metabolism in PD hONS cells to Control levels. Treatment
of 4 PD hONS cultures for 24 hr with L-SUL (0.5 or 2.5 mM)
produced an approximate 12 and 18% increase in MTS
metabolism respectively (Fig 3A). These doses of L-SUL also
increased total glutathione content by 16 and 14% (Fig 3B). At
these concentrations, L-SUL treatment was not overtly toxic
because there was no difference in caspase-3/7 activity, LDH
activity or DNA content compared to when treated with DMSO
alone (Fig 3D–F). At 10 mM, L-SUL treatment did have a slight
toxic effect, because DNA content decreased approximately 28%,
and caspase-3/7 activity and LDH activity were increased by 43%
and 180%, respectively. Although MTS metabolism was still
elevated, both total and reduced glutathione content were lower
with 10 mM L-SUL treatment (30 and 43% respectively, Fig 3B,C).
We confirmed by immunoblot that L-SUL treatment of PD
hONS cultures induced a dose-dependent increase of NRF2 levels
in three hONS cell lines derived from different PD Patients
(Fig 3G). For all three cell lines, we observed robust NRF2
increases at both 2.5 and 25 mM L-SUL treatment. No change in
the levels of the NRF2 negative regulator KEAP1 [17] was
observed at any concentration of L-SUL used. Levels of GAPDH
were unchanged at all concentrations of L-SUL, whereas b-tubulin
levels were decreased at 25 mM. We additionally confirmed that L-
SUL treatment caused a nuclear accumulation of NRF2 protein.
Immunoblot analysis of nuclear extracts prepared from these same
PD hONS cell lines treated with L-SUL (2.5 mM for 6 hours)
Figure 3. Dosage effects of L-SUL on cell metabolic function and NRF2 in PD-derived hONS cell metabolism. A–F. PD patient-derived
hONS cultures (N=4) were treated with the indicated doses of L-SUL for 24 hr and assessed for MTS metabolism (A), total glutathione (GSH) content
(B), reduced GSH content (C), DNA content (D), caspase-3/7 activity (E) and membrane integrity (LDH activity, F). Bars show mean and s.e.m., with data
presented as fold change compared to vehicle treated cultures for each cell line. For A-F, data was analysed by one-way ANOVA using Dunnett’s
multiple comparison test. The p value at the bottom of each panel indicates the ANOVA result with p,0.05 considered significant. The asterisks
above show the results of Dunnett’s multiple comparison post-tests comparing all L-SUL treated cultures to vehicle (Veh) treated cultures; * p,0.05,
*** p,0.001. G. Total protein lysates from three hONS cell lines were analysed by immunoblot for NRF2 and KEAP1. GAPDH and b-tubulin were used
as loading controls. The protein being immunodetected is indicated to the left of each gel, and the L-SUL dose and cell line are indicated above the
blot panels. H. Nuclear extracts of three hONS cell lines were analysed by immunoblot for NRF2 levels using Histone H3 as a loading control. The
protein being immunodetected is indicated to the left of each gel, and the L-SUL dose and cell line are indicated above the blot panels. I.
Quantitation of NRF2 nuclear accumulation in PD hONS cultures relative to Histone H3 protein levels; p=0.021 using one-tailed Student’s t-test. J.
NRF2 DNA binding to the ARE motif was quantified in nuclear fractions of DMSO and L-SUL treated PD hONS cell lines; p=0.041 using one-tailed
Student’s t-test.
doi:10.1371/journal.pone.0021907.g003
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lines at approximately 4 times the level of DMSO cultures, and
which also resulted in increased NRF2 DNA binding to an ARE
motif (Fig 3H–J). These results are all consistent with the known
action of L-SUL in inhibiting KEAP1-mediated proteosomal
degradation of NRF2 [19], and thus these changes in metabolic
function are likely due to decreased proteosomal degradation of
NRF2.
In order to exclude the possibility that the increases in glutathione
content and MTS metabolism induced by L-SUL were non-specific,
we used two other known NRF2 activators tert-butylhydroquinone
(tBHQ) and diethyl maleate (DEM) [19]. Treatment of PD and
Control hONS cells (N=3 per group) with 100 mMt B H Qo r5 0mM
DEM for 24 hr both significantly increased glutathione levels (Fig
S3). Similarly, both compounds increased MTS metabolism but the
increase was statistically significant only in the PD hONS cells.
Regardless of disease state, the level of induction over vehicle treated
cultures was similar for each parameter such that tBHQ and DEM
produced 60% and 70% increases, respectively, in reduced
glutathione levels in Control hONS cells compared to 90% and
80% increases in PD-derived cultures (Fig S3A–B). Similar results
were observed for the induction of total glutathione and MTS
metabolism levels (Fig S3C–F). Thus, we consistently observed
increased levels of MTS metabolism and total glutathione in hONS
cell from PD patients through activation of NRF2.
L-SUL restored metabolic deficiencies in patient-derived
hONS cells
To determine the universality of L-SUL treatment in PD hONS
cells we assessed the metabolic responses of 14 PD cultures to
24 hr treatment with 2.5 mM L-SUL. Again we observed that total
glutathione and MTS metabolism were increased (Fig 4A–B),
whereas no other assessed metabolic function (reduced GSH,
proteasome activities, ATP content, caspase-3/7 activity or LDH
activity) was altered (Fig 4C–I). Following L-SUL treatment, 86%
of the PD patient-derived cell lines (12 of 14) showed an
appreciable (at least 10%) increase in MTS and total glutathione
levels, relative to vehicle (see Table S1 for individual cell line
responses). Of these, 10 cell lines (71%) showed greater than 20%
increase in both assays. One cell line (200060004) increased both
MTS metabolism and total glutathione content, but only slightly
(8% and 7%, respectively), and one cell line (200080013) showed
no change. Notably, for the majority of PD hONS cell lines
examined, the percentage increase was sufficient to restore the
metabolic functions to that of untreated healthy Control hONS
cultures (Fig S1 and [7]). Interestingly, the observed increases in
total glutathione were not accompanied by increased levels of
reduced glutathione which remained constant, or even slightly
decreased in some lines (Fig 4C).
Metabolic changes produced by L-SUL treatment of Control
hONS cell lines were similar to those in PD hONS cell lines. In 17
Control cultures treated with 2.5 mM L-SUL for 24 hr, there was a
25% (range 9–45%) increase in total glutathione and 30% increase
(range 15–48%) increase in MTS metabolism (Fig S4A–B)
compared to DMSO treated cultures. As with PD-derived hONS
cultures, all other metabolic functions remained unchanged (Fig
S4C–I).Immunoblot analysis of 2 Controland 3 PD hONS cultures
treated with L-SUL showed similar levels of NRF2 accumulation
compared to DMSO treated cultures (Fig S4J). For all cultures
examined, this also resulted in increased NQO1 protein levels (Fig
S4J). Thus, using three different NRF2 stabilising compounds (L-
SUL, tBHQ and DEM), we observed that Control and PD hONS
cultures responded in a similar manner in terms of both magnitude
of responseand the spectrum of metabolic functions that responded.
NRF2 pathway activation increases differential gene
expression in PD and Control hONS cells
To determine the extent of changes in NRF2 target gene
expression, RNA samples were prepared from 13 PD and 16
Control hONS cultures treated for 24 hr with 2.5 mM L-SUL or
DMSO and assessed by qRT-PCR. In both Control and PD
hONS cultures, we observed that L-SUL treatment increased
mRNA levels of NRF2 target genes NQO1, GCLC and GCLM, but
that NRF2 gene expression was not altered (Fig 5A–D). All but
three PD derived cultures showed greater than 2-fold induction of
NQO1 mRNA levels on L-SUL treatment (see Table S1 for
individual cell line responses). The magnitude of GCLC and GCLM
induction was variable between cell lines (Table S1).
We next used whole-genome microarray profiling to examine in
more detail the effects of L-SUL treatment on PD and Control
hONS cell lines (ArrayExpress Accession Number E-TABM-879).
Of the 48,803 probes on the array, 14,836 passed quality control
and detection criteria. Using ANOVA on these probes, at a p-value
cut off of 0.05, 5% of probes would be significantly different by
chance (n=741). We detected 645 probe differences between
vehicle-treated PD and vehicle-treated ControlhONS. Significantly
however, these were not randomly distributed across different
expression pathways but, as previously reported [7], the NRF2
pathway was significantly different between the groups. So far we
have analysed a total of 30 PD and 24 Control hONS cell lines in
three separate experiments (7, this report and unpublished) and in
each the NRF2 pathway is significantly different in PD hONS cells.
All other comparisons (see below) were at least three times greater
thanthe741predicted bychance.Principalcomponentanalysis(Fig
S5) of the data demonstrated that L-SUL treatment was the major
driver of variance between the four experimental groups.
We hypothesised that L-SUL treatment would decrease the
dysregulation of the NRF2 pathway at the mRNA level because it
restored metabolic deficiencies in PD hONS cells. mRNA
expression data were subjected to ANOVA to assess the impact
of L-SUL treatment with main effects being treatment (+ L-SUL)
and disease status (PD versus Control). L-SUL treatment induced
significant changes in expression of 2320 mRNAs in PD hONS
cells compared to 3689 (approximately 1.6 fold more) in Control
cells (Table S2). Of these, 1075 were independent of disease state
and all but 16 had the same direction of change. In vehicle treated
cultures, 645 probes (Table S3) were differentially expressed
between PD and Control cultures, of which 219 were also
differentially expressed in the L-SUL treated cells. However, in L-
SUL treated cultures approximately four times as many mRNAs
displayed a significant difference between PD and Control cultures
(N=2647, see Table S4).
Geneset enrichment analysis using Ingenuity pathway annota-
tions revealed that the ‘NRF2-mediated oxidative stress response’
was the predominant pathway that was differentially expressed
between Control and PD cultures treated with DMSO (p=7.76E-
5) thereby replicating our initial finding [7]. Strikingly, the ‘NRF2-
mediated oxidative stress response’ was also the most dysregulated
pathway between Control and PD cultures after L-SUL treatment
(p=2.14E-9; Table S5), with many more mRNAs in this pathway
differentially expressed after treatment (47 mRNAs) than between
cultures treated with DMSO (15 mRNAs; see Fig S6A). Consistent
with genome-wide differences in the number of mRNAs
responsive to L-SUL treatment in PD and Control cultures, we
again found that approximately 1.5 times as many mRNAs within
the ‘NRF2-mediated oxidative stress response’ pathway showed
altered expression level in Control cultures after L-SUL treatment
compared to Patient cultures. The differentially expressed NRF2
pathway genes could be classified into three groups: (i) those
NRF2 Activation in Parkinson’s Disease
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(iii) those altered in Control cells alone (Fig 6A). Many genes in
each group are established NRF2 target genes, and included
NQO1 and GCLM mRNAs (consistent with our qRT-PCR results)
and other known NRF2 targets such as MAFG [23], KEAP1 [24],
GSR [25], EPHX1 [26], TXNRD1 [27], PRDX1 [28] and TXN
[29], all of which were induced in response to L-SUL treatment in
both PD and Control hONS cultures. Known NRF2 target genes
were also altered only in the PD cells (GSTM5 [30], USP14 [31]),
or only in Control cells (AKR7A2 [32,33], ATF4 [31], HMOX1
[34], SQSTM1 [35], MGST1 and MGST3 [36]).
Differences in mRNA expression between PD and Control
hONS cells after L-SUL treatment were not restricted to down-
stream NRF2 target genes, but also included signalling molecules
Figure 4. Induction of Glutathione and MTS metabolism in PD-derived hONS cell cultures. A–I. PD patient-derived hONS cultures (N=14)
were treated with 2.5 mM L-SUL for 24 hr prior to assessment of cell metabolic functions, including (A) MTS metabolism, (B–C) total and reduced
glutathione (GSH) content, (D–F) chymotrypsin-like, trypsin-like and caspase-like proteasome activities, (G) ATP content, (H) caspase3/7 activity and (I)
membrane integrity/LDH activity. Each circle (veh) or square (L-SUL treatment) represents data obtained from triplicate plates for an individual cell
line. Error bars show mean and s.e.m.. Statistical significance was determined by two-tailed t-test with Welch’s correction of vehicle versus L-SUL
treated values, with p,0.05 considered significant. Resulting p-values are shown above each graph.
doi:10.1371/journal.pone.0021907.g004
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NRF2 function. These included transcription factors such as
ATF4 [34], JUND [37] and FOS [38], as well as members of the
small MAF family [reviewed in 39], all of which can hetero-
dimerise on DNA with NRF2 and influence its transcriptional
output. We detected mRNAs for both MAFG and MAFF in hONS
cells, and consistent with previous data reporting NRF2-mediated
activation of MAFG expression [23], we found that MAFG was
induced by L-SUL in both Control and PD hONS cultures,
whereas MAFF was only induced in PD cells (Fig 6A).
L-SUL treatment also induced significant differential expression
in other pathways in PD hONS cells compared to Control cells.
Among these was the ‘PI3K/AKT signalling pathway’, which was
differentially expressed in L-SUL treated cells (p=1.10E-06), but
not in vehicle treated cells (p=0.37, see Table S5, Figure S6B).
Again, mRNAs within this pathway were divisible into three
groups: those altered in both cell types, those altered in PD cells
alone, and those altered in Control cells alone (Fig 6B). Of note
was the relatively large number of mRNAs in this pathway altered
in Control cells compared to PD cells. L-SUL treatment did alter
some pathways such that they were no longer significantly over-
represented in any particular group. For example, pathways
involved in amino acid metabolism (‘phenylalanine, tyrosine and
tryptophan biosynthesis’ and ‘glycine, serine and threonine
metabolism’) were no longer significantly differentially expressed
between control and PD-patient hONS cells (Table S5).
Thus, despite restoring identified metabolic deficiencies and
some mRNA expression levels in PD hONS cells, L-SUL
treatment also reinforced some existing transcriptional differences,
and furthermore identified pathways that were only differentially
expressed between Control donor and PD-patient derived cell
lines post-treatment.
Discussion
In this study, we show for the first time that activation of NRF2
in a novel patient-derived cellular model of idiopathic Parkinson’s
disease, previously shown to have a dysregulated NRF2 pathway
[7], could rescue disease associated metabolic functional deficits.
We firstly replicated findings of decreased levels of reduced GSH
and MTS metabolism levels in PD patient cells compared to
healthy Control cells in a larger patient cohort, and confirmed a
higher state of oxidative stress in Patient cultures. We then showed
that deactivation of NRF2 by siRNA in Control donor cells
recapitulated the PD-associated changes in metabolic function, but
that activation of the NRF2 pathway ‘rescued’ the metabolic
phenotype in the PD hONS cells. Importantly, this study is the
first to demonstrate a restorative role for NRF2 in regulating
disease-associated metabolic deficiencies, including elevation of
GSH content, in Parkinson’s disease patient-derived cells,
providing both validation and a model to further explore NRF2
as a therapeutic target for PD. Interestingly we showed that
activation of the NRF2 pathway exacerbated mRNA differences in
the same Parkinson’s disease patient and Control groups. These
disease-specific differences were observed in cells from thirteen
unrelated individuals with idiopathic disease compared with
sixteen unrelated healthy Control individuals.
In both this and our previous study [7], we have reported
differential expression of mRNAs comprising the NRF2-mediated
oxidative stress response between Control and PD hONS cell lines
under basal culture conditions, and when the NRF2 pathway is
activated. These transcriptional differences are supported by altered
protein levels and metabolic functions attributable to changes in
NRF2 functioning. We have previously proposed that underlying
genetic background differences between individual Patients and
individual Control cultures are at least in part responsible for these
observations [7]. In this regard, the ‘‘NRF2-mediated oxidative
stress response’’ is highly polymorphic, with SNPs found within
coding regions of multiple detoxification and antioxidant genes
regulated byNRF2 [40], withinAREmotifsbound byNRF2 within
many of these gene promoters [41], and within the NRF2 protein
coding region itself [42]. It may be the different combinations of
haplotypes within multiple genes comprising the NRF2 pathway
that imparts the cellular phenotype difference between Patient and
ControlhONScultures, ratherthan polymorphismor mutationof a
single gene within the pathway. Such a scenario is consistent with
the long standing association between polymorphisms within
detoxification genes and environmental (e.g. pesticides, solvents)
exposures with modifying Parkinson’s disease risk [43,44,45,46,47],
and with identification of a protective haplotype within the NRF2
gene [42].
Figure 5. Basal and L-SUL induced levels of NRF2 targets genes
in hONS cells. A–D. hONS cultures established from Control donors
(N=16) or from PD patients (N=13) were treated either with vehicle
(circles) or 2.5 mM L-SUL (squarers) for 24 hr prior to RNA extraction. The
mRNA levels of NRF2 (A), or the NRF2 target genes NQO1, GCLC and
GCLM (B–D) were measured by real-time PCR of cDNA and are
presented relative to EEF1A1. Statistical significance was determined by
2-way ANOVA. The p value at the bottom of each panel indicates the
ANOVA results comparing Control to PD hONS cultures; p,0.05 was
considered significant. The asterisks above show the results of
Bonferroni post-tests comparing DMSO and L-SUL treated cultures for
either Control or PD hONS cell; * p,0.05, *** p,0.001.
doi:10.1371/journal.pone.0021907.g005
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21907Figure 6. Transcriptomic analysis identified discrete mRNA sets induced by L-SUL in Control versus PD hONS cultures. A. Graphical
representation of the ‘NRF2-mediated oxidative stress response’ Ingenuity pathway annotation mRNA set indicating mRNAs either induced (red
icons) or repressed (green icons) by L-SUL treatment. Three discrete clusters of mRNA expression level changes were able to be identified: i) PD-
specific (blue shading), ii) Control hONS-specific (red shading) and iii) those common to both PD and Control hONS cultures (yellow shading). B.
Graphical representation of the ‘PI3K / AKT signalling’ Ingenuity pathway annotation mRNA set indicating mRNAs either induced (red icons) or
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e21907Whole organism studies have revealed a role for NRF2 in
regulating both health and lifespan [reviewed in 48], such that NRF2
function is increased in long-lived species. For example, biochemical
analysis of long-lived rodents revealed an increase in total GSH
content which was attributed to increased NRF2 protein levels [49].
In contrast, NRF2 function is reduced in the spinal cord astrocytes of
aged mice [50] and livers of aged rats [51], and can result in an age-
related decrease in GSH, a finding consistent with our results (Fig 1)
and analysis of Nrf2-null neurons [20,52]. Similar to our study, NRF2
activity in both of these aged rodent models could be induced by
treatment with exogenous chemicals, and resulted in increased GSH
content and expression of NQO1 [50,51]. In the hONS model,
NRF2 dysfunction (either by siRNA knockdown, or comparing
Patient to Control cultures) reveals a cellular phenotype that is
consistent with (i) the diminished function of NRF2 seen in aging, the
most established risk factor for Parkinson’s disease [53], and (ii) the
degenerative nature of the disease. Combined, this suggests that
decreased NRF2 activity may be involved in the pathogenesis of
Parkinson’s disease.
We have shown in this study that activation of NRF2 by L-SUL
treatment of PD-patient derived cells restored levels of GSH to Control
cell line levels (Fig 3 and 4), and that ablation of NRF2 function in
Control hONS cultures decreased GSH content (Fig 1). Decreased
levels of GSH are a recurrent finding in Parkinson’s disease brain
specimens [10,11,12], and several clinical trials have evaluated GSH
supplementation with the expectation that increased levels would be
beneficial to Parkinson’s disease patients [54,55]. Due to its
neuroprotective role and ability to increase GSH content, NRF2
activation has been a focal point of research into disease therapies
[reviewed in 18,56], although prior to the current study, the
effectiveness of this approach in any Patient-derived model had not
been examined.
Our data have also revealed a consistent decrease in MTS
metabolism in PD hONS cultures (Fig S1 and [7]), an assay
considered to reflect cellular activity of NAD(P)H-dependent
dehydrogenase enzymes [13,14]. Cellular reduction of MTS and
related compounds is often used to assay cell viability [57,58], with a
decrease in metabolism considered an indication of decreased cell
viability. Like GSH content, the decrease in MTS metabolism may
also reflect dysfunctional NRF2, as knockdown of NRF2 in Control
hONSculturesproduced a decreaseinMTSmetabolism(Fig1),and
which was also induced by L-SUL treatment (Fig 3–4). In other PD
models, several dehydrogenase enzymes have been reported to have
decreased activity, most notably the mitochondrial Complex I
NADH coenzyme-Q dehydrogenase [reviewed in 59]. This defect is
not restricted to neurons, and is alsoobserved in othercelltypes such
as platelets [60,61,62], and in cell hybrid models of Parkinson’s
disease [63]. Whilst we have not examined Complex I activity in the
hONS models, NQO1, an NAD(P)H dependent dehydrogenase
enzyme and direct NRF2 target gene, was shown to be decreased in
PD hONS cultures (Fig 2), and this may in part contribute to
diminished MTS metabolism in these cells. Decreased MTS
metabolism in PD hONS cells, as an assay of cellular dehydrogenase
activity [13,14] and/or viability [57,58] when coupled with our
NRF2 knockdown experiments (Fig 1) is therefore consistent with a
degenerative cellular phenotype. Thus, that NRF2 activation by L-
SUL, tBHQ or DEM treatment, induced MTS metabolism to
Control levels is indicative of restored metabolic function in PD
hONS cells.
Our transcriptomic analysis of Control and PD hONS cultures
revealed dysregulation of the NRF2-mediated oxidative stress
response (Table S5 and [7]). Our data suggests that NRF2
dysregulation in PD hONS cells is not due to alteration of NRF2
protein levels or the ability of NRF2 activity to be induced.
Rather, dysfunction may occur in the co-ordination of NRF2-
mediated transcriptional activation upon L-SUL-responsive pro-
moters, evidenced by transcriptomic analysis which classified the
dysregulated mRNAs into three groups (common-, PD-specific, or
Control-specific; see Fig 6A). Given our identification of discrete
sets of mRNAs induced by L-SUL in PD and Control hONS cells,
including MAFF induction by L-SUL being restricted to PD
cultures (Fig 6A), it is possible that altered NRF2-small MAF
heterodimer formation is driving the differential expression of
genes within the NRF2 pathway in hONS cells. Antagonism of
NRF2 function by small MAF proteins has been reported to occur
in co-transfection experiments using reporter constructs [64].
Consistent with these findings, knockdown of MAFG in human
hepatocellular carcinoma cells increased NRF2 DNA binding
activity and induced GSH synthetic enzymes, resulting in
increased GSH content [65]. Moreover, genetic ablation of small
Maf function in mice has revealed a requirement of these proteins
for induction of NRF2-dependent transcription [66]. Thus, the
relative abundance of small MAF proteins in a given cell may
influence the spectrum of NRF2-dependent transcription, because
some target genes appear to have different sensitivities to depletion
of specific Maf genes [66,67]. Interestingly, MafG
2/2:MafK
+/2
mice display a neuronal degeneration, including aggregations of
ubiquitylated proteins, both earlier, and with a higher penetrance
than mice null for only MafG [67,68]. Investigation of small MAF
function in the hONS model may implicate this family of proteins
in Parkinson’s disease pathology.
Another novel finding was that L-SUL treatment resulted in
significant differential mRNA expression changes within several
pathways, in a disease-specific manner. These were not evident in
vehicle-treated cultures (Table S5). Whether such pathway
responses are a direct consequence of NRF2 dysfunction, or are
an NRF2-independent difference in the response of PD hONS
cells to L-SUL remains to be determined. Of note however, are
some pathways with relevance to Parkinson’s disease. Inhibition of
PI3K signalling can reduce NRF2 nuclear translocation and
antioxidant gene induction in neuroblastoma cells [69,70], and
can also inhibit the antioxidant-induced binding of NRF2 to gene
promoters, allowing BACH1 to remain associated with the
antioxidant response element and repress transcription [71].
Impaired PI3K/AKT signalling has been reported in Drosophila
models of PD in which either DJ-1 or Parkin were suppressed by
RNAi [72] and in PD patient-derived lymphoblast cultures
carrying the DJ-1 L166P mutant [73]. When combined with our
current study, these findings suggest convergence of genetic and
idiopathic mechanisms of PD manifestation on PI3K signalling.
Whilst our hONS cell model reflects several molecular changes
frequently reported in PD [7], it is a possibility that the rescue of
deficient metabolic functions in hONS cultures by activation of the
NRF2 pathway may not occur in other cell types, specifically
neurons. However, the key trigger for the disease may reside in non-
neuronal cells. This is evidenced in humans by the development of
PD-like changes in previously healthy grafted neurons [74,75] and
inrodentstudies that show astrocyte-restricted re-expression ofNrf2
in Nrf2-null mice is sufficient to mitigate the neurodegenerative
repressed (green icons) by L-SUL treatment. Three discrete clusters of mRNA expression level changes were able to be identified: i) PD-specific (blue
shading), ii) Control hONS-specific (red shading) and iii) those common to both PD and Control hONS cultures (yellow shading).
doi:10.1371/journal.pone.0021907.g006
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patient derived hONS cells have altered NRF2-mediated responses
compared to Controls raises the possibility that NRF2 dys-
regulation may be widespread in PD, and not restricted to neurons.
In conclusion, we have for the first time demonstrated that PD
patient-derived cells have alterations in NRF2 signalling revealed
by cellular responses to activators of this pathway. In our hONS
model, NRF2 pathway activation restored disease-specific deficits
in cellular functions (glutathione content and MTS metabolism),
however gene expression profiling suggests a concomitant further
distortion of a disease-altered genetic network. These results
further demonstrate the utility of hONS cultures for understanding
disease-associated changes in the cell biology of idiopathic
Parkinson’s disease. In particular, hONS cultures may be suitable
for pre-clinical testing of pharmaceuticals targeting NRF2 for
disease therapy.
Materials and Methods
Ethics Statement
All donor tissue and information was obtained with the
informed, written consent of the participants and all procedures
were in accordance with National Health and Medical Research
Council Code of Practice for Human Experimentation and
approved by the Griffith University Human Experimentation
Ethics Committee.
Participants and nasal biopsies
Patients with PD (N=28) were recruited from consumer groups
and through research participant registers maintained by the
Queensland Centre for Mental Health Research and the Queens-
land Parkinson’s Project. Controls (N=26) were recruited from
the general population. The patients were diagnosed by a
movement disorders neurologist according to UK Brain Bank
criteria. Controls completed the same questionnaire as patients to
exclude undiagnosed PD. None of the healthy Controls was on PD
medication. Olfactory biopsies were obtained by a specialist
otorhinolaryngologist according to published protocols [5].
Cell culture
hONS cell lines from PD patients and healthy Control donors
wereestablishedaspreviouslydescribed[7].Olfactoryneurospheres
were generated from primary cultures of olfactory mucosa plated
onto poly-L-lysine (Sigma) coated tissue culture plates in serum-free
DMEM/F12 (Invitrogen) medium containing 50 ng/mL EGF
(Sigma) and 25 ng/mL FGF2 (Sigma). Neurospheres were collected
and dissociated for subsequent propagation as adherent monolayers
in DMEM/F12 medium containing 10% FBS (GibcoBRL) to
produce hONS cell lines.
For all experimental procedures, hONS cell lines were grown in
10% FBS in DMEM/F12 to provide sufficient numbers, harvested
by enzymatic detachment, washed 36in 10% FBS in DMEM/F12,
and counted as described [7]. For metabolic functional assays, hONS
cells were plated in 96 well plates at a density of 2500 cells per well in
100 mL of medium and allowed to attach overnight. For total protein
and RNA extractions, hONS cultures were seeded into 6-well plates
at a density of 1.2610
5 cells per well in 2 mL of medium. For all
experiments, medium was changed the day following cell seeding,
and replaced with either normal growth medium (basal PD
compared to Control assessment), or replaced with medium
containing DMSO as vehicle or indicated concentrations of NRF2
modulators.
L-SUL (Sigma) was dissolved in DMSO, and both t-BHQ
(Sigma) and DEM (Sigma) were dissolved in ethanol. Final solvent
concentration in tissue culture medium did not exceed 0.1%.
Treated cells were compared to cells treated in parallel with
equivalent volumes of vehicle in the medium.
siRNA transfection
Control donor derived hONS cells were plated in antibiotic-free
growth medium at densities indicated above and allowed to attach
overnight. The following day, 7.5 mL of DharmaFECT reagent 1
transfection reagent (Dharmacon), or siRNAs (final concentration
50 nM) were diluted into 200 mL medium and incubated at room
temperature for 5 minutes. Diluted siRNAs were added to diluted
transfection reagent, and incubated for a further 20 minutes at room
temperature, and 600 mL of normal growth medium was added to
the mixture. Transfection mixture volumes were scaled as appropri-
ate. Medium was aspirated from the cells, and prepared liposomes
added to appropriate wells (1 mL per well for 6 well plates, 50 mLp e r
well for 96 well plates) and the cells incubated at 37uCi n5 %C O 2.
Five hrs post addition of liposomes, an equal volume of normal
growth medium was added to each well, and the transfection
continued overnight. The following day, the liposomes were
removed, and replaced with normal growth medium, or with
medium supplemented with vehicleor NRF2 inducing compounds as
appropriate. NRF2 target sequences (Dharmacon) were UAAA-
GUGGCUGCUCAGAAU (NRF2 siRNA #09) and GAGUUA-
CAGUGUCUUAAUA(NRF2siRNA#10).Asa negativecontrol,a
non-targeting sequence (Dharmacon) was used. All assays were
conducted 48 hrs post-transfection.
Immunoblot
Cells were plated and treated as described above. Following
appropriate incubation times, total protein lysates were prepared
using SDS-PAGE lysis buffer containing 16 HALT protease/
phosphatase inhibitors (Pierce) and 10–15 mg total protein per lane
assayed by SDS-PAGE and immunoblot as described [76].
Membranes were blocked in 5% milk in TBST for 1 hr at room
temperature. Primary antibodies were incubated overnight at 4uC
and included anti-NQO1 (1:3000, Stressgen), anti-KEAP1 (1:250,
R&D Systems), and anti-NRF2 (1:1000, Epitomics). Anti-GAPDH
(1:10000, Trevigen) and anti-b-tubulin (1:2000, Sigma) were used
as loading controls and were incubated at room temperature for
2 hrs. Antibody binding was detected and visualised using either
anti-rabbit-IgG or anti-mouse-IgG HRP-conjugated secondary
antibodies, ECL reagent (Millipore) and a digital imaging station
(VersaDoc, BioRad).
Nuclear extraction and DNA binding assay
Nuclear extracts were prepared from DMSO or L-SUL treated
cultures using a commercially available kit following the manufac-
turer’s instructions (Pierce) with the inclusion of an additional wash of
the nuclear fraction in CERI buffer prior to nuclei lysis with NER
buffer. Equal amounts of extract were electrophoresed on 4–20%
Tris-glycine gradient SDS-PAGE gels (BIORAD), proteins trans-
ferred to PVDF and immunoblotted for NRF2 as described above.
Histone H3 antibody (1:1000, Cell Signalling Technology) was used
as a loading control. NRF2 DNA binding was assessed using an
ELISA-based assay using immobilised oligonucleotides correspond-
ing to the consensus ARE motif from the human NQO1 promoter
according to the manufacturer’s instructions (Active Motif). Briefly,
equal amounts of nuclear extract were incubated with the
oligonucleotide for 1 hr at RT. After washing, bound NRF2 was
detected using the supplied NRF2 antibody followed by peroxidase-
conjugated secondary antibody. Antibody binding was detected by
addition of developing solution for 15 min at which time the reaction
was stopped, and the absorbance at 450 nm recorded using 690 nm
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triplicate, and data presentedas fold-increase in DNAbinding activity
compared to respective DMSO treated control signal.
Cell-based metabolic assays
Cells were plated and treated as described above. Following
appropriate incubation times, metabolic functions were assessed
essentially as per manufacturer supplied protocols, with only
minor modifications as described previously [7]. For determina-
tion of total glutathione content, TCEP (1 mM final concentra-
tion) was added to the reaction buffer. Chymotrypsin-like, trypsin-
like and caspase-like proteasome activities were all determined
using the same protocols, with different activities based on
substrate selectivity (Promega). For all assays, average background
signal was subtracted from all other values for each assay, and data
were normalised to DNA content (determined via CyQUANT-NF
assay, Invitrogen). For each cell line and assay, triplicate values
from duplicate experiments were averaged and a signal:DNA
content ratio determined.
H2O2 levels in cell culture medium was assayed using 10-acetyl-
3,7-dihydroxyphenoxazine (ADHP), a highly sensitive and stable
probe for H2O2 which in the presence of horseradish peroxidase,
reacts with H2O2 to produce resorufin. Briefly, 50 mL of prepared
assay reagent (40 nM ADHP and 0.8 mg/mL peroxidase in PBS)
was added to 100 mL of cell culture medium. After incubation at
RT for 10 min in darkness, fluorescence emission at 590 nm was
recorded after excitation at 530 nm using a microplate reader.
Real-time PCR
RNA was extracted using commercially available kits (QIA-
GEN). Total RNA (2 mg) was reverse transcribed using Super-
Script III first-strand synthesis system (Invitrogen). Levels of
mRNAs were quantified and normalised against EEF1A1 using a
relative quantification approach with primer efficiency correction
as described [7]. PCR conditions were 95uC for 10 minutes
followed by 40 cycles at 95uC for 15 seconds, 58uC for 10 seconds
and 72uC for 10 seconds. Primer sequences were CYP1A1; F-
cacatgctgaccctgggaaag, R-ggtgtggagccaattcggatc; CYP1B1;F -
cggccactatcactgacatc, R-ctcgagtctgcacatcagga; NQO1; F-cagct-
caccgagagcctagt, R-gagtgagccagtacgatcagtg; GCLC; F-atgccatgg-
gatttggaat, R-agatatactgcaggcttggaatg; GCLM; F-tgggcacagg-
taaaaccaa, R-cagtcaaatctggtggcatc; NRF2; F-acacggtccacagctcatc,
R-tgtcaatcaaatccatgtcctg; EEF1A1: F-ccccaggacacagagacttt, R-
gcccattcttggagatacca.
Microarray hybridisation and analysis
Whole genome arrays were performed on 16 Control and 13
PD hONS cultures, with each cell line treated with either DMSO
or 2.5 mM L-SUL for 24 hr prior to RNA extraction (described
above). RNA quantity and quality was accessed by Nanodrop
(Thermo Scientific) and Agilent 2100 Bioanalyser (RNA Nano
chips). Samples were labelled with Ambion Illumina RNA
amplification kit using 500 ng of RNA and a 4 h IVT as per the
manufactures instructions (Ambion). Labelled cRNA (750 ng) was
hybridized to Illumina Human-HT-12 version 3 BeadChips
(Illumina) for 16 hours and scanned on an Illumina Beadstation.
Raw bead data were summarized in GenomeStudio V2009.1 and
exported with no additional processing. Raw summarized data
were background corrected and quantile normalized using the
lumi package (http://www.bioconductor.org/packages/2.0/bioc/
vignettes/lumi/inst/doc/lumi.pdf) in R/BioConductor. Normal-
ised data were imported into and analysed in Genespring GX
7.3.1. software (Agilent Technologies). Data were filtered using
Illumina detection p-value. A probe was included in further
analysis if it had a detection p-value of #0.01 in 25% of samples
within the four groups (PD vehicle, Control vehicle, PD L-SUL
treated and Control L-SUL treated). Cell line expression patterns
were investigated using principal component analysis. Differential
expression was determined using ANOVA comparing Control and
PD hONS transcriptomes from either vehicle or L-SUL treated
cultures. Pathway over-representation analysis was determined
using right-tailed Fisher’s exact test using Ingenuity Pathway
Analysis (IPA) 8.5 (Ingenuity Systems). Microarray data was
deposited into ArrayExpress (Accession Number E-TABM-879),
and is MIAME compliant.
Supporting Information
Figure S1 Cell metabolism deficiencies in PD-patient
derived hONS cultures. A–F. hONS cultures established from
Control donors (N=26) or from PD patients (N=28) were
assessed for levels of reduced glutathione (GSH) content, MTS
metabolism, ATP content, chymotrypsin-like proteasome activity,
caspase-3/7 activity and membrane integrity (LDH activity). Each
circle (Cont) or square (PD) represents the average value for each
assay after normalisation to DNA content for a given cell line, each
assayed in triplicate on two occasions. Bars show mean and
standard error of the mean (s.e.m.). Statistical significance was
assessed using an unpaired two-tailed t-test with Welch’s
correction, with p,0.05 considered significant. Resulting p-values
are shown above each graph. G. H2O2 levels in culture medium
from either Control or Patient hONS cultures (N=8 in each
group) at 24, 48, 72 and 96 hours after cell seeding. Results are
representative of 2 independent experiments that showed similar
results. Statistical significance was assessed on time-point matched
data between Controls and PD Patient values using an unpaired
two-tailed t-test with Welch’s correction, with p,0.05 considered
significant; *, p,0.05; **, p,0.01.
(TIF)
Figure S2 Lack of correlations of hONS cell metabolism
with donor age or cell line passage number. A. Gender of
hONS cell line donors. B–C. Age (B) and cell line passage number
(C) did not differ between Control and PD patient groups
(p=0.076 and p= 0.84 respectively, two tailed-t-test with p,0.05
considered significant). Each circle (control) or square (PD)
represents an individual donor. Lack or correlation of cell
metabolic function and donor age (D–I) or cell line passage
number (J–O). Each circle represents data from an individual
donor plotted against that donors’ age or the number of passages
for the derived cell line prior to assay. Linear regression analyses
were conducted in Prizm 5 for Windows (GraphPad).
(TIF)
Figure S3 Comparison of known NRF2 activators. tBHQ
(100 mM) and DEM (50 mM) were assessed for their ability to alter
PD-associated metabolic deficiencies in Control (N=3) and PD
(N=3) hONS cell lines. Cells were treated with indicated
compounds for 24 hr prior to determination of reduced glutathi-
one (GSH) content (A–B), total GSH content (C–D), or MTS
metabolism (E–F). Bars show mean and s.e.m., with data
presented as fold change compared to vehicle treated cultures
for each cell line. Statistical significance was determined by
ANOVA. *, p,0.05; **, p,0.01; ***, p,0.001; N.S. = not
significant.
(TIF)
Figure S4 Induction of GSH and MTS metabolism in
Control donor-hONS cultures. Control donor-derived hONS
cultures (N=17) were treated with 2.5 mM L-SUL for 24 hr prior
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metabolism (A), total and reduced glutathione (GSH) content
(B–C), chymotrypsin-like, trypsin-like and caspase-likeproteasome
activities (D–F), ATP content (G), caspase3/7 activity (H) and
membrane integrity/LDH activity (I). Each circle (veh) or square
(L-SUL treatment) represents data obtained from triplicate plates
for an individual cell line. Error bars show mean and s.e.m..
Statistical significance was determined by two-tailed t-test with
Welch’s correction of vehicle versus L-SUL treated values, with
p,0.05 considered significant. Resulting p-values are shown
above each graph. J. Immunoblot analysis of total protein lysates
from 2 Control and 3 PD hONS cultures treated with either
DMSO (2) or 2.5 mM L-SUL (+) for 48 hrs. The protein being
detected is shown to the left of each gel panel.
(TIF)
Figure S5 Principle component analysis of mRNA
expression changes in L-SUL treated hONS cultures.
Principle component analysis plot of the behaviour of each cell line
sample relative to the major drivers of gene expression. The
components are component 1: vehicle treatment, component 2: L-
SUL treatment and component 3: disease status. This plot shows
that L-SUL treatment is the primary driver of gene expression
differences between groups, but there is also some segregation of
the samples on disease status, though this is less well defined.
(TIF)
Figure S6 Transcriptomic analysis identified discrete
mRNA sets induced by L-SUL in Control versus PD
hONS cultures. A. Graphical representation of the `NRF2-
mediated oxidative stress response’ Ingenuity pathway annotation
mRNA set post-L-SUL treatment, indicating those mRNAs either
similarly expressed (clear icons), more highly expressed in PD
hONS cultures (red icons) or more highly expressed in Control
cultures (green icons). mRNAs identified as differentially expressed
between Control and PD hONS cultures in vehicle treated
cultures are indicated (red background shading), with those no
longer differentially expressed in L-SUL cultures indicated (blue
background shading). B. Graphical representation of the`PI3K /
AKT signalling’ Ingenuity pathway annotation mRNA set post-L-
SUL treatment, indicating those mRNAs either similarly
expressed (clear icons), more highly expressed in PD hONS
cultures (red icons) or more highly expressed in Control cultures
(green icons).
(TIF)
Table S1 Individual PD-derived hONS cell line meta-
bolic and qRT-PCR responses to 24 hr treatment with
2.5 mM L-SUL.
(DOC)
Table S2 Gene expression changes in Control and PD-
derived hONS cell lines.
(XLS)
Table S3 Fold-change gene expression changes in
Vehicle-treated hONS cell lines.
(XLS)
Table S4 Fold-change gene expression changes in L-
SUL-treated hONS cell lines.
(XLS)
Table S5 Geneset enrichment of Pathway Annotations
based on Disease Status or Treatment Status.
(XLS)
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